UTRECHT, The Netherlands, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage
immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg,
Ph.D., Chief Executive Officer, will participate at two upcoming investor conferences in September:
- Citi’s 12th Annual Biotech Conference on Thursday, September 7, 2017 at the Mandarin Oriental Hotel in Boston, MA
- LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology on Thursday, September 28, 2017 at the Lotte New York
Palace Hotel in New York, NY
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics,
referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard
processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies,
such as long half-life and low immunogenicity. Merus’ lead bispecific antibody candidate, MCLA-128, is expected to begin a Phase 2
combination trial in the second half of 2017 in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a
Phase 1/2 clinical trial in Europe in gastric, ovarian, endometrial and non-small cell lung cancers. Merus’ second bispecific
antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company
also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed
to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well
as MCLA-145 designed to bind to PD-L1 and a non-disclosed second immunomodulatory target, which is being developed in collaboration
with Incyte Corporation.
Contacts: Media: Eliza Schleifstein +1 973 361 1546 eliza@argotpartners.com Investors: Kimberly Minarovich +1 646 368 8014 kimberly@argotpartners.com
